-
公开(公告)号：US11806321B2
公开(公告)日：2023-11-07
申请号：US18185045
申请日：2023-03-16
IPC分类号： A61K31/166 , A61P25/00 , A61P35/00 , A61K9/00
CPC分类号： A61K31/166 , A61K9/0053 , A61P25/00 , A61P35/00
摘要： The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
-
公开(公告)号：US20230293462A1
公开(公告)日：2023-09-21
申请号：US18185045
申请日：2023-03-16
IPC分类号： A61K31/166 , A61K9/00 , A61P35/00 , A61P25/00
CPC分类号： A61K31/166 , A61K9/0053 , A61P35/00 , A61P25/00
摘要： The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
-
3.发明公开公开(公告)号：US20240058282A1
公开(公告)日：2024-02-22
申请号：US18357988
申请日：2023-07-24
IPC分类号： A61K31/166 , A61K9/00 , A61K31/216 , A61K45/06 , A61P25/00 , A61P35/00
CPC分类号： A61K31/166 , A61K9/0053 , A61K31/216 , A61K45/06 , A61P25/00 , A61P35/00
摘要： The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11883375B2
公开(公告)日：2024-01-30
申请号：US18334518
申请日：2023-06-14
IPC分类号： A61K31/166 , A61P35/00 , A61K45/06 , A61K9/00 , A61K31/216 , A61P25/00
CPC分类号： A61K31/166 , A61K9/0053 , A61K31/216 , A61K45/06 , A61P25/00 , A61P35/00
摘要： The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
-
公开(公告)号：US20230293466A1
公开(公告)日：2023-09-21
申请号：US18186312
申请日：2023-03-20
IPC分类号： A61K31/166 , A61P35/00 , A61K9/00
CPC分类号： A61K31/166 , A61P35/00 , A61K9/0053
摘要： The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
-
公开(公告)号：US11819487B2
公开(公告)日：2023-11-21
申请号：US18185080
申请日：2023-03-16
IPC分类号： A61K31/216 , A61P35/00
CPC分类号： A61K31/216 , A61P35/00
摘要： The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20230321013A1
公开(公告)日：2023-10-12
申请号：US18185148
申请日：2023-03-16
IPC分类号： A61K31/166 , A61P35/00 , A61K9/00
CPC分类号： A61K31/166 , A61K9/0053 , A61P35/00
摘要： The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF 1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
-
8.发明公开公开(公告)号：US20230293472A1
公开(公告)日：2023-09-21
申请号：US18185080
申请日：2023-03-16
IPC分类号： A61K31/216 , A61P35/00
CPC分类号： A61K31/216 , A61P35/00
摘要： The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20230321014A1
公开(公告)日：2023-10-12
申请号：US18334518
申请日：2023-06-14
IPC分类号： A61K31/166 , A61P35/00 , A61K9/00
CPC分类号： A61K31/166 , A61P35/00 , A61K9/0053
摘要： The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
-
公开(公告)号：US20230293464A1
公开(公告)日：2023-09-21
申请号：US18185225
申请日：2023-03-16
发明人： Badreddin Edris , Collin Todd , Todd Shearer , Nenad Sarapa , Mary Smith
IPC分类号： A61K31/166 , A61K9/00 , A61K45/06 , A61P35/00
CPC分类号： A61K31/166 , A61K9/0053 , A61K45/06 , A61P35/00
摘要： The present disclosure relates to methods for treating pancreatic ductal adenocarcinoma comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.014 秒)
